Fact CheckerSign in

NCT03567213Recruiting

Investigation on the Cortical Communication (CortiCom) System

Source: ClinicalTrials.gov · Last updated 21 Aug 2026

Brief summary (registry, in English)

The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up to 128 channels, for six months. In each participant, the grid(s) will be implanted over areas of cortex that encode speech and upper extremity movement.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
3 (estimated)
First submitted
21 May 2018
Start date
14 Dec 2021
Primary completion date
31 Dec 2028
Lead sponsor
Johns Hopkins University
NCT number
NCT03567213

What you commit to

  • Study type: Interventional
  • Planned participants: 3
  • From 14 Dec 2021 to the primary completion date, 31 Dec 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Presence of pre-surgical findings in anatomical, functional, and/or vascular neuroimaging that makes achieving implant locations within desired risk levels too challenging (to be decided by neurological and neurosurgical team)
  • Prior cranioplasty
  • Chronic oral or intravenous use of steroids or immunosuppressive therapy
  • Participants in whom it is medically contraindicated to stop anti-coagulant medications during surgery

Other illness

  • Performance on formal neuropsychological testing that indicates significant psychiatric conditions or cognitive impairments that would interfere with obtaining informed consent or fully participating in study activities.
  • Implanted devices that are incompatible with MRI, which may include pacemakers, cardiac defibrillators, spinal cord or vagal nerve stimulators, deep brain stimulators, and cochlear implants.
  • History of substance abuse, narcotic dependence, or alcohol dependence in past 24 months
  • Medical conditions contraindicating surgery of a chronically implanted device (e.g. osteomyelitis, diabetes, hepatitis, any autoimmune disease/disorder, epilepsy, skin disorders causing excessive skin sloughing or poor wound healing, blood or cardiac disorder requiring chronic anti-coagulation)
  • Other chronic, unstable medical conditions that could interfere with subject participation.
  • Participants with active infections or unexplained fever
  • Participants with other morbid conditions making the implantation of the recording elements unsafe; not limited to: significant pulmonary, cardiovascular, metabolic, or renal impairments making the surgical procedure unsafe
  • HIV or AIDS infection
  • Active cancer within the past year or requires chemotherapy

Other

  • Suicide attempt or persistent suicidal ideation within the past 12 months.
  • Inability to undergo MRI or anticipated need for an MRI during the study period
  • Pregnancy (confirmation through blood test)
  • Nursing an infant, planning to become pregnant, or not using adequate birth control
  • Corrected vision poorer than 20/100
  • Existing scalp lesions or skin breakdown
  • Uncontrolled autonomic dysreflexia within the past 3 months
  • Hydrocephalus with or without an implanted ventricular shunt

Who the study is looking for

  • Clinical diagnosis of tetraplegia (quadriplegia), brainstem stroke , amyotrophic lateral sclerosis (ALS) or Locked-in Syndrome (LIS)
  • Tetraplegia diagnosis, ALS diagnosis, stroke, or LIS etiology onset occurred at least one year prior to enrollment
  • Complete or incomplete tetraplegia (quadriplegia), tetraparesis (quadriparesis), or severe ataxia. In addition, these motor impairments may be combined with severe motor-related speech impairment (dysarthria or anarthria), as in LIS.
  • 22-70 years
  • Meeting surgical safety criteria, including surgical clearance by the participant's primary healthcare provider, study physicians, and any necessary consultants
  • Ability to communicate reliably, such as through eye movement
  • Willingness and ability to provide informed consent
  • Screened by rehabilitation psychologist with a result showing that the participant has a stable psychosocial support system with caregiver capable of monitoring participant throughout the study
  • Ability and willingness to travel up to 100 miles to study location up to three days per week for the duration of the study
  • Ability to understand and comply with study session instructions
  • Participant consents to the study and still wishes to participate at the time of the study

Age in the registry: 22 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Johns Hopkins Medicine
Coordinator of this site? Confirm its status
BaltimoreUnited StatesRecruiting

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.